Clinical Trial Search

Primary: Change in Systemic Vascular Resistance Index (SVRI) to Pulmonary Vascular Resistance Index (PVRI) Ratio (Rp:Rs Ratio) — 0.8; 0.75; 0.61; 0.73 Rp:Rs ratio — p=0.9

Primary: Peak 6-minute Walk Distance — 366.0; 360.0; 21.6; 3.0 meters — p=0.00044

Primary: Cardiac Glucose Uptake in FDG-PET (Fluorodeoxyglucose-Positron Emission Tomography) — 1.0; 0.6; 0.9; 0.8 standardized uptake value (SUV) — p=0.04

Primary: Maximum Change From Baseline in Supine Systolic Blood Pressure (SBP) Within 4 Hours Post-dose at Visit 6 (Week 12) — -20.70; -20.20 mmHg

Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week 24, as Measured by Right Heart Catheterization (RHC) — 35; -28; -21; 6 dyne*sec/cm^5 — p== 0.214

Primary: Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR) — 0.46; 0.48 ratio — p=0.4239

Primary: Transthoracic Echocardiogram (ECHO)-Based Change in the Tricuspid Annular Plane Systolic Excursion (TAPSE) Measurement — 2.244; 2.244; 2.300; 2.212 mm

Primary: Dose-limiting Toxicities — 0; 0; 0; 0 Participants

Primary: 6-minute-walk Distance (6MWD) — 330.0; 328.6 meters — p=0.7883

Primary: Change From Baseline in Pulmonary Vascular Resistance Index (PVRI) at Week 16 — 18.567; -4.113 wood units*meter^2

Primary: 6 Minute Walk Distance — 230 meters

Primary: Mean Pulmonary Arterial Pressure Change From Baseline — -1.0; -0.73 mmHg

Primary: Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR) — 21.2; -74.9 dyne•s/cm^5 — p=0.0310

Primary: Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks — 1.28 mL/min/kg

Primary: Percent Change in Mean Pulmonary Artery Pressure in the Whole Cohort. — -25 percent change

Primary: Percentage of Subjects With Sustained Treatment Transition — 82.4 Percentage of participants

Primary: Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks — -27.6; -168.4; -258.9; 802.0 dynes*sec/cm^5 — p=0.0030

Primary: Number of Patients Reaching a 6-Minute Walk Test (6MWT) Distance ≥ 380 Meters — 16; 24 participants

Primary: Change in Exercise Pulmonary Hemodynamics From Baseline to Week 24 — 37.4 mmHg — p=.0008

Primary: Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks — 382.94; 351.18 meters

Primary: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 11; 8; 8; 2 participants

Primary: Change in Pulmonary Vascular Resistance — 7.1 percent difference from baseline

Primary: Right Ventricular (RV) Mass — 32.5; 28.0 grams

Primary: Change in 6 Minute Walk Test — 7.00; 16.60; 16.00; 4.90 Meters walked in 6 minutes

Primary: Pulmonary Vascular Resistance (PVR) — 6.7 woods unit

Primary: Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) — 80.1; 89.3…

Primary: Categorized Change From Baseline in 6-Minute Walking Distance — 27; 46; 20; 26 participants

Primary: Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake — 91.2; 81.7; 83.1; 70.6 Percentage of patients…

Primary: Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population — 6.44; 13.40; 10.58; 10.24 percent change — p=0.056

Primary: Change From Baseline in Distance Walked During a Six Minute Walk Test — 23.6; 0.5 Meters — p=0.12